



February 06, 2025

To,

**BSE Limited**  
25, P. J. Towers,  
Dalal Street,  
Mumbai – 400 001  
**Scrip Code: 500120**

**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G,  
Bandra — Kurla Complex, Bandra (E)  
Mumbai — 400 051  
**Symbol: DIAMINESQ**

**Sub:** Integrated Filing (Financial) for the quarter ended December 31, 2024

Respected Sir / Ma'am,

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31 2024; read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 02 2025; we are submitting herewith the Integrated Filing (Financial) for the quarter and nine months ended on December 31, 2024.

Kindly take the same on record.

Thanking You,

Yours Faithfully,  
For Diamines and Chemicals Limited

Hemaxi Pawar  
Company Secretary  
Membership No.: A52581

**B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.**

<b>Statement on deviation / variation in utilisation of funds raised</b>	
<b>Name of listed entity</b>	Diamines And Chemicals Limited
<b>Mode of Fund Raising</b>	<del>Public Issues / Rights Issues / Preferential Issues / QIP / Others</del>
<b>Date of Raising Funds</b>	October 01, 2024 (Date of Allotment)
<b>Amount Raised</b>	₹ 50.58 Cr (100% of issue) *
<b>Report filed for Quarter ended</b>	December 31, 2024
<b>Monitoring Agency</b>	<b>applicable / not applicable</b>
<b>Monitoring Agency Name, if applicable</b>	Not Applicable
<b>Is there a Deviation / Variation in use of funds raised</b>	Yes / No
<b>If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders</b>	Not Applicable
<b>If Yes, Date of shareholder Approval</b>	Not Applicable
<b>Explanation for the Deviation / Variation</b>	Not Applicable
<b>Comments of the Audit Committee after review</b>	None
<b>Comments of the auditors, if any</b>	None
<b>Objects for which funds have been raised and where there has been a deviation, in the following table</b>	

Original Object	Modified Object, if any	Original Allocation (Rs in Crores)	Modified allocation, if any	Funds Utilised (Rs in Crores)	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
capital expenditures, working capital requirements, acquisition, investment in technology and for general corporate purpose	NA	50.58	NA	-	-	12.51 crores received (i.e. 25% of the issue)
<p><b>Deviation or variation could mean:</b></p> <p>(a) Deviation in the objects or purposes for which the funds have been raised or</p> <p>(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or</p> <p>(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.</p>						
<p><b>Hemaxi Pawar</b> <b>Company Secretary</b></p>						

\*Note: The Company had received In-Principle approval on September 19, 2024 for issue not exceeding 916390 number of convertible warrants at Rs. 552 per warrant. The Board, in its meeting held on October 01, 2024, had allotted 906390 convertible warrants on receipt of subscription money Rs. 12.51 crores i.e. 25% of the total Issue, on preferential basis to the investors.



- C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES – **Not Applicable**
  
- D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) – **Not Applicable**
  
- E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) – **Not Applicable**